Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

Systemic therapy often results in the reduction of tumor size but rarely succeeds in
eradicating all cancer cells. Drug efflux, persistence of cancer stem cells (CSCs), epithelial …

Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …

Opinion statement Melanoma is caused by a variety of somatic mutations, and among these
mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a …

Neuroblastoma evolution, heterogeneity, and resistance remain inadequately defined,
suggesting a role for circulating tumor DNA (ctDNA) sequencing. To define the utility of …

Background Development of resistance to targeted therapies has tempered initial optimism
that precision oncology would improve poor outcomes for cancer patients. Resistance …

Although temozolomide (TMZ) provides significant clinical benefit for glioblastoma (GBM),
responses are limited by the emergence of acquired resistance. Here, we demonstrate that …

Over the last decade, anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase (RTK),
has been identified as a fusion partner in a diverse variety of translocation events resulting …

Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) show potent efficacy in
several ALK-driven tumors, but the development of resistance limits their long-term clinical …

Human lung adenosquamous cell carcinoma (LUAS), containing both adenomatous and
squamous pathologies, exhibits strong cancer plasticity. We find that ALK rearrangement is …